El-Hai, A., Nassar, A., Salem, A., Saleh, R. (2022). Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction. The Egyptian Journal of Hospital Medicine, 89(2), 7749-7759. doi: 10.21608/ejhm.2022.277135
Abeer Abd El-Hai; Abd El Malek Nassar; Ahmed S. Salem; Rania M. Saleh. "Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction". The Egyptian Journal of Hospital Medicine, 89, 2, 2022, 7749-7759. doi: 10.21608/ejhm.2022.277135
El-Hai, A., Nassar, A., Salem, A., Saleh, R. (2022). 'Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction', The Egyptian Journal of Hospital Medicine, 89(2), pp. 7749-7759. doi: 10.21608/ejhm.2022.277135
El-Hai, A., Nassar, A., Salem, A., Saleh, R. Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction. The Egyptian Journal of Hospital Medicine, 2022; 89(2): 7749-7759. doi: 10.21608/ejhm.2022.277135
Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction
1Clinical Pathology Department, Faculty of Medicine Suez Canal University Hospital, Ismailia, Egypt
22 Cardiology Department, Faculty of Science, Ismailia, Egypt
3Clinical Pathology Department, Faculty of Medicine Suez Canal University Hospital, Ismailia, Egypt.
Abstract
Background: The "gold standard" approach for diagnosing myocardial infarction (MI) in patients with a high risk of the condition is cardiac troponins T or I (cTnT or cTnI), which are more accurate than CK-MB for myocardial damage. In addition to these well-known biomarkers, several intriguing biomarkers have gained attention in MI over the past few years. Soluble suppression of tumorigenicity-2 (sST-2), also known as Interleukin-1 receptor-like 1 (IL-1RL-1) is one of such biomarkers. Aim: this study aimed to assess the association of sST-2 with acute MI among Egyptian population. Patients and methods:A total of 72 individuals were enrolled in the study, including thirty-six patients with MI and thirty-six healthy normal controls. sST-2 was measured by ELISA in both groups. sST-2 was measured in patients with MI at two occasions: during first 24 hours of chest pain and 30 days after. Results: sST-2 level was higher in MI patients compared to normal controls. The level of sST-2 declined after 30 days after attack compared to day one. A positive correlation was found between serum level of sST-2 and cardiac marker of necrosis: serum CK (r = 0.65, p <0.001), CK-MB (r= 0.51, p= 0.001), and LDH (r= 057, p < 0.001). Soluble ST-2 was negatively correlated with ventricular ejection fraction (r= -0.40, p=0.015). We found that a cut-off value of 150 pg/ml for sST-2 denoted the presence of MI with 86.11% sensitivity and 80.56% specificity (p < 0.001). ROC curve was plotted for serum sST-2 to indicate the development of complications after MI sets a threshold value of 3100 pg/ml with 90% sensitivity and 96.15% specificity (p < 0.001). Conclusions: sST-2 is a potential biomarker for acute myocardial infarction (AMI) and possible predictors for the risk of myocardial damage in the Egyptian population.
View on SCiNiTO
Top